PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search

Search

Reset

BNF Chapter

BNF Paragraph

Please select a BNF Chapter.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results : Diabetes Mellitus (Dapagliflozin - Diabetes Mellitus)

Records returned : 76 (on 19 Apr 2025 at 21:30:49). .

Drug
Indication
Status
Trust Alignment
Links
Restrictions/Comments
06.01.02
Dapagliflozin
Diabetes Mellitus
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Type 2 diabetes. Empagliflozin is the preferred SGLT-2 Dapagliflozin is not a preferred treatment option. Trusts restrict to diabetic team initiation only.
06.01.02
Diabetes Mellitus
Non Formulary
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Not licensed in Type 1 diabetes. Not to be initiated in new Type 1 patients. Shared care remains in place for existing patients only.
06.01.02
Repaglinide
Diabetes Mellitus
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
06.01.02
Pioglitazone hydrochloride
Diabetes Mellitus
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
06.01.02
Metformin hydrochloride
Diabetes Mellitus
Green
Formulations :
  • Modified release tablets
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Preferred
NOTE: 1g oridnary tablets are disproportionately expensive in primary care. 1g modified release tablets are recommended.
06.01.02
Sitagliptin
Diabetes Mellitus
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Preferred
06.01.02
Dulaglutide
Diabetes Mellitus
Green
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Preferred
Preferred GLP-1 for WEEKLY injection.
06.01.02
Diabetes Mellitus
Green
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
06.01.02
Gliclazide
Diabetes Mellitus
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Preferred
06.01.02
Empagliflozin
Diabetes Mellitus
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Preferred
06.01.01
Insulin aspart - NovoRapid
(Insulin)
Diabetes Mellitus
Green
Formulations :
  • Pre-filled pen
  • Cartridges
  • Vials
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Biosimilar insulin aspart (Trurapi) should be used in preference to NovoRapid. Prescribe by brand and state form.
06.01.01
Insulin glargine - Abasaglar
(Insulin)
Diabetes Mellitus
Green
Formulations :
  • Pre-filled pen
  • Cartridges
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Prescribe by brand and state form. Semglee (biosimilar) is a lower cost option for patients using a pre-filled pen.
06.01.01
Insulin Lispro - Admelog
(Insulin)
Diabetes Mellitus
Green
Formulations :
  • Pre-filled pen
  • Cartridges
  • Vials
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Biosimilar insulin Lispro (Admelog). Prescribe by brand and state form.
06.01.01
Soluble insulin - Actrapid
(Insulin)
Diabetes Mellitus
Green
Formulations :
  • Vials
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
06.01.01
Soluble insulin - Humulin S
(Insulin)
Diabetes Mellitus
Green
Formulations :
  • Cartridges
  • Vials
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Prescribe by brand and state form.
06.01.01
Isophane Insulin - Insulatard
(Insulin)
Diabetes Mellitus
Green
Formulations :
  • Cartridges
  • Vials
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Prescribe by brand and state form.
06.01.01
Isophane Insulin - Humulin I
(Insulin)
Diabetes Mellitus
Green
Formulations :
  • Pre-filled pen
  • Cartridges
  • Vials
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Prescribe by brand and state form.
06.01.01
Insulin glargine - Lantus
(Insulin)
Diabetes Mellitus
Green
Formulations :
  • Pre-filled pen
  • Cartridges
  • Vials
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Prescribe by brand and state form. Semglee (biosimilar) is a lower cost option for patients using a pre-filled pen. Lantus remains an option in existing patients and those preferring a reusable pen.
06.01.01
Insulin glargine - Semglee
(Insulin)
Diabetes Mellitus
Green
Formulations :
  • Pre-filled pen
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Preferred
Semglee (biosimilar insulin glargine) is the preferred brand for all new patients who require a pre-filled pen. Prescribe by brand. Note - Semglee is NOT available as cartridges for use in re-usable insulin pens.
06.01.01
Biphasic Isophane Insulin - Humulin M3
(Insulin)
Diabetes Mellitus
Green
Formulations :
  • Pre-filled pen
  • Cartridges
  • Vials
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Prescribe by brand and state form.
06.01.01
Biphasic Insulin Aspart - Novmix 30
(Insulin)
Diabetes Mellitus
Green
Formulations :
  • Pre-filled pen
  • Cartridges
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Prescribe by brand and state form.
06.01.01
Biphasic Lispro Insulin - Humalog Mix 25
(Insulin)
Diabetes Mellitus
Green
Formulations :
  • Pre-filled pen
  • Cartridges
  • Vials
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Prescribe by brand and state form.
06.01.01
Biphasic Lispro Insulin - Humalog Mix 50
(Insulin)
Diabetes Mellitus
Green
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Prescribe by brand and state form.
06.01.01
Insulin glulisine - Apidra
(Insulin)
Diabetes Mellitus
Green
Formulations :
  • Pre-filled pen
  • Cartridges
  • Vials
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Prescribe by brand and state form. SASH - restricted to diabetes team initiation only.
06.01.01
Insulin Lispro - Humalog
(Insulin)
Diabetes Mellitus
Green
Formulations :
  • Pre-filled pen
  • Cartridges
  • Vials
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Prescribe by brand and state form. Admelog (biosimilar insulin lispro) is lower cost and should be considered in preference to Humalog.
06.01.01
Insulin Lispro - Lyumjev
(Insulin)
Diabetes Mellitus
Green
Formulations :
  • Pre-filled pen
  • Cartridges
  • Vials
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Prescribe by brand and state form.
06.01.01
Insulin Aspart - Trurapi
(Insulin)
Diabetes Mellitus
Green
Formulations :
  • Pre-filled pen
  • Cartridges
  • Vials
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Preferred
Prescribe by brand and state form. Lower-cost biosimilar. Preferred for new patients.
06.01.02
Ertugliflozin
Diabetes Mellitus
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Empagliflozin is the preferred SGLT-2. Ertugliflozin is a treatment option. Trusts restrict to diabetic team initiation only.
06.01.02
Semaglutide
Diabetes Mellitus
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Oral semaglutide is not a preferred route due to poor availability and gastrointestinal side effects. Use may be appropriate in a small cohort of patients where injection isn't suitable.
06.01.02
Gliclazide
Diabetes Mellitus
Green (see narrative)
Formulations :
  • Modified release
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Immediate release tablets are preferred
06.01.02
Exenatide
Diabetes Mellitus
Green (see narrative)
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Exenatide is not a preferred treatment option. The preferred GLP-1 for WEEKLY injection is dulaglutide. Prescribing may continue on existing patients.
06.01.02
Semaglutide
Diabetes Mellitus
Green (see narrative)
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Dulaglutide is 1st line. Semaglutide is the 2nd line option for WEEKLY injection. Max of 13 Ozempic pens per patient per year (1 pen is a 4 week supply).
06.01.02
Semaglutide (oral)
Diabetes Mellitus
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Oral semaglutide is not a preferred route due to poor availability and gastrointestinal side effects. Use may be appropriate in a small cohort of patients where injection isn't suitable.
06.01.02
Linagliptin/metformin
Diabetes Mellitus
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Reserve combination products for patients in whom the separate components are less appropriate
06.01.02
Linagliptin
Diabetes Mellitus
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Sitagliptin is 1st line. Only consider linagliptin in patients with rapidly deteriorating renal function where there is a risk that dose reduction of sitagliptin may not take place.
06.01.02
Metformin hydrochloride
Diabetes Mellitus
Green (see narrative)
Formulations :
  • Oral solution
  • Powder
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Oral solution should be reserved for patients with enteral feeding tubes or those unable to swallow tablets. Sachets of powder for oral solution are preferred in patients with swallowing difficulties in primary care.
06.01.02
Metformin hydrochloride/sitagliptin
Diabetes Mellitus
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Reserve combination products for patients in whom the separate components are less appropriate
06.01.02
Glimepiride
Diabetes Mellitus
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Not a preferred treatment option.
06.01.02
Tirzepatide
Diabetes Mellitus
Green (see narrative)
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
Dulaglutide is the preferred weekly injection. Semaglutide is an alternative for weekly injections. Tirzepatide is 3rd line where dulaglutide / semaglutide are unsuitable or unavailable.
06.01.02
Liraglutide
Diabetes Mellitus
Green (see narrative)
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Preferred
Liraglutide is 1st-line for patients who wish to have a DAILY injection. Dulaglutide is the preferred WEEKLY injection.
06.01.02
Acarbose
Diabetes Mellitus
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Inadequately controlled diabetes mellitus
06.01.02
Empagliflozin/metformin
Diabetes Mellitus
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Reserve combination products for patients in whom separate components are less appropriate. Existing patients would not be expected to change therapy unless appropriate to do so.
06.01.02
Dapagliflozin/metformin
Diabetes Mellitus
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Empagliflozin is the preferred SGLT2. Reserve combination products for patients in whom separate components are less appropriate.
06.01.01
Insulin detemir
(Insulin)
Diabetes Mellitus
Green (see narrative)
Formulations :
  • Pre-filled pen
  • Cartridges
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Levemir (insulin detemir Penfill / FlexPen) is being discontinued. Supplies are expected to run out by Dec 2026. It is recommended that this is not initiated in new patients.
06.01.01
Insulin Aspart - Fiasp
(Insulin)
Diabetes Mellitus
Blue
Formulations :
  • Pre-filled pen
  • Cartridges
  • Vials
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Prescribe by brand and state form. SASH - restricted to diabetes team initiation only.
06.01.01
Insulin Glargine - Toujeo
(Insulin)
Diabetes Mellitus
Blue
Formulations :
  • Pre-filled pen
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Initiation by diabetes consultants or GPs with a specialist interest in diabetes. For use in poorly controlled patients.
06.01.01
Isophane (neutral insulin) - hypurin porcine 30/70
(Insulin)
Diabetes Mellitus
Blue
Formulations :
  • Cartridges
  • Vials
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Initiation by diabetes team only. Usage is low but available for existing patients
06.01.01
Soluble insulin - Hypurin porcine neutral
(Insulin)
Diabetes Mellitus
Blue
Formulations :
  • Cartridges
  • Vials
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Initiation by diabetes team only
06.01.01
Insulin degludec
(Insulin)
Diabetes Mellitus
Blue
Formulations :
  • Pre-filled pen
  • Cartridges
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Initiation by Diabetes team only. Prescribe by brand. Insulin degludec is available in strengths of 100units/mL and 200units/mL - ensure correct strength is prescribed and dispensed
02.05.01
06.01.04
Diazoxide
Diabetes Mellitus
Red
Formulations :
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Always used in combination with chlorothiazide.
02.05.01
06.01.04
Diabetes Mellitus
Red
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Unlicensed product
06.01.04
Glucose
Diabetes Mellitus
Red
Formulations :
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Glucose 250mg per ml (75g in 300ml) Not supplied by Pharmacy at SASH - ordered from NHS Procurement
Insulin pump - Type 1 diabetes
Diabetes Mellitus
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
06.01.02
Glibenclamide
Diabetes Mellitus
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
SASH restricted to specialist monogenic clinic for use in specific diabetic subtypes (unlicensed drug - hospital only prescribing)
06.01.02
Dulaglutide
Diabetes Mellitus
N/A
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
06.01.02
Semaglutide (oral)
Diabetes Mellitus
N/A
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
06.01.02
Exenatide
Diabetes Mellitus
N/A
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
06.01.01
Suliqua (Insulin glargine/lixisenatide)
Diabetes Mellitus
Non Formulary
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
06.01.01
Xultophy
Diabetes Mellitus
Non Formulary
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
06.01.02
Tolbutamide
Diabetes Mellitus
Non Formulary
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
06.01.02
Glipizide
Diabetes Mellitus
Non Formulary
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
06.01.02
Saxagliptin
Diabetes Mellitus
Non Formulary
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Existing patients would not be expected to change therapy unless appropriate to do so.
06.01.02
Alogliptin
Diabetes Mellitus
Non Formulary
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Existing patients would not be expected to change therapy unless appropriate to do so.
06.01.02
Vildagliptin
Diabetes Mellitus
Non Formulary
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Existing patients would not be expected to change therapy unless appropriate to do so.
06.01.02
Metformin hydrochloride/vildagliptin
Diabetes Mellitus
Non Formulary
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Sitagliptin is the preferred DPP4. Reserve combination products for patients in whom separate components are less appropriate. Existing patients would not be expected to change therapy unless appropriate to do so.
06.01.02
Alogliptin/metformin
Diabetes Mellitus
Non Formulary
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Sitagliptin is the preferred DPP4. Reserve combination products for patients in whom separate components are less appropriate. Existing patients would not be expected to change therapy unless appropriate to do so.
06.01.02
06.01.04
Glyxambi (Linagliptin/empagliflozin)
Diabetes Mellitus
Non Formulary
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
06.01.02
Saxagliptin/dapagliflozin
Diabetes Mellitus
Non Formulary
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
06.01.02
Canagliflozin/metformin
Diabetes Mellitus
Non Formulary
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Empagliflozin is the preferred SGLT2.
Sotagliflozin
Diabetes Mellitus
Non Formulary
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Sotagliflozin is not yet available in the NHS. The NICE TA622 will not be implemented until the product is available. Place in therapy will also be determined at this time.
06.01.02
Metformin hydrochloride/pioglitazone
Diabetes Mellitus
Non Formulary
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Not a cost-effective option. Prescribe as separate components.
02.05.01
06.01.04
Diazoxide
Diabetes Mellitus
Non Formulary
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
06.01.01
Soluble insulin - Humulin R
(Insulin)
Diabetes Mellitus
Non Formulary
Formulations :
  • Pre-filled pen
  • Vials
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
06.01.01
Isophane Insulin - Hypurin Porcine Isophane
(Insulin)
Diabetes Mellitus
Non Formulary
Formulations :
  • Cartridges
  • Vials
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
06.01.02
Albiglutide
Diabetes Mellitus
See Below
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
06.01.02
Semaglutide (oral)
Diabetes Mellitus
See narrative
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
 

For information about the icons and status values within this site, please refer to the keys below.

Icon/Links Key

NFD1
Non formulary
NFD2
Not assessed for formulary status. Apply to APC / DTC before use.
CD
Controlled drug. Prescribing and/or storage requirements may apply
R
Restrictions apply
SA
Safety Alert
U
Unlicensed - no UK marketing license in place
Un
Off-label use. Not licensed for this indication.
NHSE
Treatment commissioned by NHS England
CDF
CDF
ICB
Treatment commissioned by the ICB
BlueTeq
BlueTeq form to be completed
NICE
NICE

Traffic Light Status Key

Red
Specialist ONLY drugs - treatment initiated and continued by specialist clinicians
Amber
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement
Green
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.
Black
Now referred to as "Non Formulary" but some BLACK drugs remain pending review. Not recommended for use in any health setting across Surrey and NW Sussex health economy.
Amber Star
Now referred to as "Blue" but some Amber Star drugs remain pending review. Prescribing initiated and stabliised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green (see narrative)
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.
Non Formulary
Not recommended for use in any health setting across Surrey and NW Sussex health economy. (Formerly BLACK traffic light status)
See Below
Please add a description.
N/A
Please add a description.
Blue
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green - Black
Now referred to as "Do not initiate in new patients" but some GREEN/BLACK drugs remain pending review. These drugs are NOT for new initiations (BLACK, (now referred to as Non Formulary)) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required.
See narrative
See narrative - is applied in instances where there may be more than one traffic light status for a drug. This occurs when the traffic light status may differ between specific cohorts of patients e.g. those of childbearing potential and those who are not (in the case of sodium valproate)
Do not initiate in new patients
These drugs are NOT for new initiations (Non Formulary) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required. (Formerly GREEN/BLACK traffic light status)
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More